Safety of Infliximab Following Live Virus Vaccination in Kawasaki Disease Patients

No published data are available regarding infliximab use in Kawasaki disease patients with recent live virus vaccination. We investigated 38 acute Kawasaki disease patients who received infliximab within 90 days of receiving measles-mumps-rubella, varicella-zoster virus, or Rotavirus vaccines. There...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Pediatric infectious disease journal 2017-04, Vol.36 (4), p.435-437
Hauptverfasser:	Lee, Aaron M, Burns, Jane C, Tremoulet, Adriana H
Format:	Artikel
Sprache:	eng
Schlagworte:	Chickenpox Vaccine Child Child, Preschool Humans Infant Infliximab - adverse effects Infliximab - therapeutic use Measles-Mumps-Rubella Vaccine Mucocutaneous Lymph Node Syndrome - drug therapy Mucocutaneous Lymph Node Syndrome - epidemiology Prospective Studies Rotavirus Vaccines Vaccination - statistics & numerical data
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	No published data are available regarding infliximab use in Kawasaki disease patients with recent live virus vaccination. We investigated 38 acute Kawasaki disease patients who received infliximab within 90 days of receiving measles-mumps-rubella, varicella-zoster virus, or Rotavirus vaccines. There were no adverse events or serious infections, which suggests that infliximab use in acute Kawasaki disease patients with recent live viral vaccinations is safe.
ISSN:	0891-3668 1532-0987
DOI:	10.1097/INF.0000000000001447